Anti-TNF agents for the treatment of spondyloarthropathies

Bibliography

• BRAUN J, BOLLOW M, REMLINGER G et al.: Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritis Rheum. (1998) 41:58–67.
   PubMed Web of Science ®Google Scholar
• •Showing that SpA are more prevalent than thought before.
   Google Scholar
• BRANDT J, BOLLOW M, HABERLE J et al.: Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (1999) 38:831–836.
   PubMed Web of Science ®Google Scholar
• GRAN JT, HUSBY G, HORDVIK M: Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, Northern Norway. Ann. Rheum. Dis. (1985) 44:359–367.
   PubMed Web of Science ®Google Scholar
• SARAUX A, GUEDES C, ALLAIN J et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. Rheumatol. (1999) 26:2622–2627.
   Web of Science ®Google Scholar
• ZINK A, BRAUN J, LISTING J, WOLLENHAUPT J: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. Rheumatol. (2000) 27:613–622.
   Web of Science ®Google Scholar
• ZINK A, LISTING J, KLINDWORTH C, ZEIDLER H: The national database of the German Collaborative Arthritis Centres: I. Structure, aims and patients. Ann. Rheum. Dis. (2001) 60:199–206.
   PubMed Web of Science ®Google Scholar
• BOONEN A, CHORUS A, MIEDEMA H, VAN DER HEIJDE D, VAN DER TEMPEL H, VAN DER LINDEN S: Employment, work disability and work days lost in patients with ankylosing spondylitis: a cross-sectional study of Dutch patients. Ann. Rheum. Dis. (2001) 60:353–358.
   PubMed Web of Science ®Google Scholar
• •One of the first studies investigating the socioeconomic impact of AS.
   Google Scholar
• WARD MM: Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. (1999) 12:247–255.
   PubMed Web of Science ®Google Scholar
• AMOR B, DOUGADOS M, MIJIYAWA M: Criteria for the classification of spondylarthropathies. Rev Rhum. Mal. Osteoartic. (1990) 57:85–89.
   PubMedGoogle Scholar
• AMOR B, SANTOS RS, NAHAL R, LISTRAT V, DOUGADOS M: Predictive factors for the long-term outcome of spondyloarthropathies. .1 Rheumatol. (1994) 21:1883–1887.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, BEHIER JM, JOL CHINE I et al.: Efficacy of celecoxib, a cyclooxygenase-2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal anti-inflammatory drug. Arthritic Rheum. (2001) 44:180–185.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, GUEGUEN A, NAKACHE JP et al.: Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 week weeks nonsteroidal anti-inflammatory drug trial. Rheumatology (1999) 38:235–244.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, VAN DER LINDEN S, LEIRISALO-REPO M et al: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritic Rheum. (1995) 38:618–627.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, ABDELLATIF M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritic Rheum. (1999) 42:2325–2329.
   PubMed Web of Science ®Google Scholar
• NISSILA M, LEHTINEN K, LEIRISALO-REPO M, LUUKKAINEN R, MUTRU O, YLI-KERTTULA U: Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritic Rheum. (1988) 31:1111–1116.
   PubMed Web of Science ®Google Scholar
• BENITEZ-DEL-CASTILLO JM, GARCIA-SANCHEZ J, IRADIER T, BANARES A: Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (2000) 14:340–343.
   PubMed Web of Science ®Google Scholar
• ROYCHOWDHURY B, BINTLEY-BAGOT S, HUNT J, TUNN EJ: Methotrexate in severe ankylosing spondylitis: a randomised placebo-controlled, double-blind observer study. Rheumatology (2001) 40:43.
   Google Scholar
• WARD MM, KUZIS S: Treatment used by patients with with ankylosing spondylitis: comparison with treatment preferences by rheumatologists.Rheumatol. (1999) 5:1–8.
   Web of Science ®Google Scholar
• •This study shows rather surprisingly that many rheumatologists use DMARDs despite the lack of scientific evidence that they are effective.
   Google Scholar
• LEIRISALO-REPO M: Prognosis, course of disease and treatment of the spondyloarthropathies. Rheum. Dis. North Am. (1998) 24:737–751.
   PubMed Web of Science ®Google Scholar
• UEO T, KOBORI K, OKUMURA H et al.: Effectiveness of lymphocytapheresis in a patient with ankylosing spondylitis. Transfus. Sci. (1990) 11:97–101.
   PubMedGoogle Scholar
• JANTUNEN E, MYLLYKANGAS-LUOSUJARVI R, KAIPIAINEN-SEPPANEN O, NOUSIAINEN T: Autologous stem Cell Transplantation in a lymphoma patient with a long history of ankylosing spondylitis. Rheumatology (2000) 39:563–564.
   PubMed Web of Science ®Google Scholar
• KOCH B, KRANZHOFER N, PFREUNDSCHU M, PEES HW, TRUMPER L: First manifestations of seronegative spondylarthropathy following autologous stem Cell Transplantation in HLA-B27-positive patients. Bone Marrow Transplant. (2000) 26:673–675.
   PubMed Web of Science ®Google Scholar
• MERCADO U: The use of methylprednisolone pulse therapy in a severe case of HLA-B27 negative ankylosing spondylitis. Rheumatol. (1994) 211:582–583.
   Google Scholar
• PLANT MJ, BORG AA, DZIEDZIC K, SAKLATVALA J, DAWES PT: Radiographic patterns and response to corticosteroid hip injection. Ann. Rheum. Dis. (1997) 56:476–480.
   PubMed Web of Science ®Google Scholar
• MAUGARS Y, MATHIS C, BERTHELOT JM, CHARLIER C, PROST A: Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br. Rheumatol. (1996) 35:767–770.
   PubMedGoogle Scholar
• BRAUN J, BOLLOW M, SEYREKBASAN F et al.: Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. Rheumatol. (1996) 23:659–664.
   Web of Science ®Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, FITZGERALD AA: A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal anti-inflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum. (2002) 46:766-773. 28. BRAUN J, LEMMEL M, MANGER B, RAU R, SORENSEN H, SIEPER J: Therapy of ankylosing spondylitis with Radiumchloride. Z Rheumatol. (2001) 60:74–83.
   PubMed Web of Science ®Google Scholar
• GRATACOS J, COLLADO A, FILELLA Xet al: Serum cytokines (IL-6, TNF-a, IL-13 and IFN-y) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br. Rheumatol. (1994) 33:927–931.
   PubMedGoogle Scholar
• BRAUN J, KHAN MA, SIEPER J: Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann. Rheum. Dis. (2000) 59:985–994.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BOLLOW M, EGGENS U, KONIG H, DISTLER A, SIEPER J: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. (1994) 37:1039–1045.
   PubMed Web of Science ®Google Scholar
• •Introducing magnetic resonance imaging to detect and quantify acute inflammation in AS.
   Google Scholar
• MCGONAGLE D, GIBBON W, O'CONNOR P, GREEN M, PEASE C, EMERY P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. (1998) 41:694–700.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38:499–505.
   PubMed Web of Science ®Google Scholar
• ••This study shows that TNF-a is highlyexpressed in the inflamed sacroiliac joint.
   Google Scholar
• FRANCOIS RJ, GARDNER DL, DEGRAVE EJ, BY WATERS EG: Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. (2000) 43:2011–2024.
   PubMed Web of Science ®Google Scholar
• BOLLOW M, FISCHER T, REI13HAUERH, SIEPERJ, HAMM B, BRAUN J: T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann. Rheum. Dis. (2000) 59:135–140.
   PubMed Web of Science ®Google Scholar
• DE VOS M, CUVELIER C, MIELANTS H, VEYS E, BARBIER F, ELEWAUT A: Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology (1989) 96:339–344.
   PubMed Web of Science ®Google Scholar
• MIELANTS H, VEYS EM, CUVELIER C, DE VOS M: Course of gut inflammation in spondylarthropathies and therapeutic consequences. BalBeres Chia. Rheumatol (1996) 10:147–164.
   PubMed Web of Science ®Google Scholar
• MAY E, MARKER-HERMANN E, WITTIG BM, ZEITZ M, MEYER ZUM BUSCHENFELDE KH, DUCHMANN R: Identical T cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology (2000) 119: 1745–1755.
   Google Scholar
• HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. (2002) 359:1541–1549.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121:1088–1094.
   PubMed Web of Science ®Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932–1939.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of Rheumatoid Arthritis with a Recombinant Human Tumour Necrosis Factor Receptor (p75) -Fc Fusion Protein. N Engl. I Med. (1997) 337:141–148.
   PubMed Web of Science ®Google Scholar
• LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al:Infliximab and methotrexate in the treatment of rheumatoid arthritis. AntiTumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl. I Med. (2000) 343:1594–1602.
   PubMed Web of Science ®Google Scholar
• GARRETT S, JENKINSON TR, KENNEDY LG, WHITELOCK HC, GAISFORD P, CALIN A: A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. I Rheumatol (1994) 21:2286–2291.
   Google Scholar
• ••A new disease activity index for AS wasdefined which is now widely used in clinical treatment studies.
   Google Scholar
• VAN DER HEIJDE D, BELLAMY N, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S: Preliminary core sets for end points in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. Rheumatol (1997) 24:2225–2229.
   Web of Science ®Google Scholar
• •Further progress in defining end points for AS treatment studies.
   Google Scholar
• ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, FELSON M: ASAS preliminary criteria for short-term improvement in ankylosing spondylitis. Arthritic Rheum. (2001) 44:1878–1886.
   Web of Science ®Google Scholar
• BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the antitumour necrosis factor alpha monoclonal antibody infliximab. Arthritic Rheum. (2000) 43: 1346–1352.
   Google Scholar
• •First open study demonstrating the surprisingly good effect of infliximab for the treatment of AS.
   Google Scholar
• BRANDT J, HAIBEL H, REDDIG J, SIEPERJ, BRAUN J: Treatment of patients with severe ankylosing spondylitis with infliximab - a one year follow-up. Arthritis Rheum. (2001) 44:2936–2937.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS EM: Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59:428–433.
   PubMed Web of Science ®Google Scholar
• •This open study shows that infliximab is effective in different subsets of SpA.
   Google Scholar
• STONE M, SALONEN D, LAX M, PAYNE U, LAPP V, INMAN R: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. .1 Rheumatol (2001) 28:1605–1614.
   PubMed Web of Science ®Google Scholar
• MAKSYMOWYCH WP, JHANGRI GS, LAMBERT RG et al: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. Rheumatol (2002) 29:959–965.
   Web of Science ®Google Scholar
• BREBAN MA, VIGNON E CLAUDEPIERRE P et at. Efficacy of Infliximab in severe refractory ankylosing spondylitis (AS). Results of an open-label study. Ann. Rheum. Dis. (2001) 60 (Suppl.):59.
   Google Scholar
• COLLANTESE, MC MUNOZ-VILLANUEVA R SANMARTI JD et al.: Infliximab in refractory spondyloarthropathies, preliminary results in Spanish population. Ann. Rheum. Dis. (2001) 60(Suppl.):59–60.
   Google Scholar
• ALLALI F, ROUX C, KOLTA S et al.: Infliximab in the treatment of spondylarthropathy, bone mineral density effect. Arthritis Rheum. (2001) 44(9):589.
   Google Scholar
• KRUITHOF E, VAN DEN BOSCH F, BAETEN D et al.: Repeated infusions of infliximab, a chimeric antiTNF-alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow-up. Ann. Rheum. Dis. (2002) 61:207–212.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multi-centre trial. Lancet. (2002) 359:1187–1193.
   PubMed Web of Science ®Google Scholar
• ••First placebo-controlled trial withinfliximab in AS showing a very good effect compared to placebo.
   Google Scholar
• VAN DEN BOSCH F, KRUITHOF E, BAETEN D et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. (2002) 46:755–765.
   PubMed Web of Science ®Google Scholar
• ••Placebo-controlled trial with infliximabconfirming the good effect of infliximab in different forms of SpA.
   Google Scholar
• MIELANTS H: Treatment of refractory SpA/AS with TNF-a blockers: the Belgian experience. Lecture presented at: International Workshop on New Treatment Strategies M Ankylosing Spondylitis (2002) Berlin, Germany.
   Google Scholar
• BRANDT J, HAIBEL H, REDDIG J, SIEPER J, BRAUN J: Successful treatment of severe undifferentiated spondyloarthropathy with the antitumour necrosis factor a monoclonal antibody infliximab. I Rheumatol (2002) 29:118–122.
   Web of Science ®Google Scholar
• •Open study showing that infliximab is effective in uSpA.
   Google Scholar
• MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. (2001) 44:2112–2117.
   PubMed Web of Science ®Google Scholar
• •Open study demonstrating that etanercept is effective in various forms of SpA.
   Google Scholar
• GORMAN JD, SACK KE, DAVIS JC: Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2000) 43:S403.
   Web of Science ®Google Scholar
• ••Placebo-controlled study with an open extension phase which shows clear superiority of etanercept over placebo in the treatment of AS.
   Google Scholar
• BRANDT J, KARIOUZOV A, LISTING J et al.: Six months results of a German double-blind placebo-controlled, Phase III clinical trial of etanercept in active ankylosing spondylitis. Ann. Rheum. Drs. (2002) 61 (Suppl. 1):41.
   Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356:385–90.
   PubMed Web of Science ®Google Scholar
• ••Placebo-controlled 3-month trialdemonstrating a high response of etanercept compared to placebo in the treatment of patients with PsA.
   Google Scholar
• ANTONI C, DECHANT C, LORENZ et al.: Open-label study of infliximab for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritic Rheum. (2002) 47:506–512.
   PubMed Web of Science ®Google Scholar
• •Similar good effect of infliximab in PsA patients in this open study.
   Google Scholar
• BOSCHF VAN DEN, KRUITHOF E, DE VOS M, DE KEYSER F, MIELANTS H: Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet (2000) 356(9244):1821–1822.
   PubMed Web of Science ®Google Scholar
• •Efficacy of infliximab in arthritis/ spondylitis in Crohn's disease in four patients.
   Google Scholar
• DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritic Rheum. (1991) 34:1218–1227.
   PubMed Web of Science ®Google Scholar
• MAU W, ZEIDLER H, MAU R et al.: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J. Rheumatol (1988) 15:1109–1114.
   PubMed Web of Science ®Google Scholar
• SMITH JR, LEVINSON RD, HOLLANDGN et al.: Differential efficacy of tumour necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritic Rheum. (2001) 45:252–257.
   PubMed Web of Science ®Google Scholar
• EL-SHABRAWI Y, HERMANN J: AntiTNFa Therapy with infliximab in the treatment of HLA B27 associated acute anterior uveitis — a one year follow-up. Arthritic Rheum. (2001) 44:S425.
   Google Scholar
• KEANE J, GERSHON S, WISE RP et al:Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl. J. Med. (2001) 345:1098–1104.
   PubMed Web of Science ®Google Scholar
• HUANG F, GU J, ZHAO W, ZHU J, ZHANG J, YU DT: One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritic Rheum. (2002) 47:249–254.
   PubMed Web of Science ®Google Scholar